Xenon Pharmaceuticals (XENE) Stock
Clinical stage drug developer for rare neurological disorders. Here's the price, business snapshot, and what's worth knowing about Xenon Pharmaceuticals in June 2026.
Xenon Pharmaceuticals Inc (XENE) is a clinical-stage biotechnology company focusing on developing small-molecule therapies for neurological and rare disorders. The company’s research centres on ion-channel biology and precision modulation of neuronal activity, with a pipeline of candidates in various stages of clinical development. With a market capitalisation of about $3.32 billion, Xenon combines laboratory research, clinical trials and regulatory engagement as it seeks to advance programmes toward potential approvals. Investors should note the typical biotech profile: outcomes hinge on trial results, regulatory decisions and successful commercial execution. Clinical progress can drive share price moves, but programmes may also fail or require additional funding. This summary provides general information for educational purposes only and is not personalised investment advice. Consider your risk tolerance and consult a qualified financial adviser before making investment decisions, as biotech stocks can be volatile and carry substantial downside as well as upside potential.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying XENON's stock with a target price of $55.55, indicating potential growth.
Financial Health
Xenon Pharmaceuticals is performing well financially, with strong cash flow and a solid book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring XENE
The Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: 15 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline progress to watch
Clinical trial milestones and data releases can materially influence valuation; positive results may lift sentiment, though outcomes are uncertain and can disappoint.
Ion-channel innovation
Xenon’s science centres on ion-channel modulation, a specialised approach that could address unmet needs but also faces scientific and regulatory hurdles.
Regulatory and funding dynamics
Regulatory approvals and financing rounds shape the company’s path to market; investors should be aware of potential dilution and timeline risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
